Billiontoone Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Billiontoone Inc in the second quarter 2026?
Billiontoone Inc achieved a return on average equity (ROE) of 10.45 % in its second quarter 2026, this is above BLLN's average return on equity of 0%.
Billiontoone Inc shareholder's equity over the 12 months ending in its second quarter 2026 are valued at $321 million

ROE decreased relative to the period ending , due to the decline in net income.

Within the Medical Laboratories industry Billiontoone Inc achieved the highest return on equity. While the total ranking for ROE unchanged, relative to the first quarter 2026 at no. .

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	-	-	-	-	-
Y / Y Net Income Change	-	-95.67 %	-98.52 %	-	-
Net Income (TTM) in Millions	34	25	423	821	820
Return On Equity (TTM)	10.45 %	20.39 %	-	-	-
BLLN's Total Ranking	#	#	#	#	#
Equity (TTM) in Millions	537	506	480	-240	-252
Seq. Equity Change	6.17 %	5.31 %	-	-	-
Seq. Net Income Change	-55.18 %	200.65 %	296.62 %	-	-

Back to BLLN Management Effectiveness >> BLLN's 5 Years Annual ROE >> Compare BLLN ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	#
Sector	#
Overall	#

Return On Equity Statistics
High	Average	Low
0 %	0 %	0 %

BLLN Annual Return On Equity	(Dec 31 2025) 2025
Total Equity in Millions	480	0	0	0	0
Y / Y Equity Change	-	-	-	-	-
Net Income in Millions	3	0	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	0.61 %	-	-	-	-

Back to BLLN Management Effectiveness >> BLLN's 5 Years Annual ROE >> Compare BLLN ROE to its Competitors

Annual Roe Comment

In 2025 ROE fell to 0.61 %, despite net income growth.

More Return On Equity Ratios
Medical Laboratories Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
BLLN's' Return on Equity at Yahoo Finance
BLLN's Roe Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for BLLN's Competitors
Subscribers only: Roe for Billiontoone Inc 's Suppliers
Subscribers only: Return On Equity for BLLN's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Pacs Group Inc	27.00 %
Sotera Health Company	26.75 %
Insulet Corporation	26.69 %
Bioventus Inc	25.96 %
Johnson and Johnson	25.74 %
Encompass Health Corporation	25.52 %
Resmed Inc	24.21 %
Healthcare Services Group Inc	24.12 %
Electromed Inc	23.65 %
Iradimed Corporation	23.45 %
Vertex Pharmaceuticals Inc	23.31 %
Lantheus Holdings Inc	23.27 %
Msa Safety Inc	23.15 %
Prestige Consumer Healthcare Inc	21.77 %
Jazz Pharmaceuticals Plc	21.37 %
Neurocrine Biosciences Inc	21.13 %
Universal Health Services Inc	20.89 %
Puma Biotechnology Inc	20.85 %
Entera Bio Ltd	20.82 %
United Therapeutics Corporation	20.18 %
Ligand Pharmaceuticals Incorporated	20.06 %
Harmony Biosciences Holdings inc	20.06 %
Pediatrix Medical Group Inc	19.89 %
Theravance Biopharma inc	19.40 %
Krystal Biotech Inc	19.34 %
Ani Pharmaceuticals Inc	19.33 %
Brightspring Health Services Inc	18.93 %
Sbc Medical Group Holdings Incorporated	18.69 %
West Pharmaceutical Services Inc	18.51 %
Intuitive Surgical Inc	17.82 %

Date modified: 2026-09-08T15:11:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.